Bookmark This Page | E-mail This Page | Print This Page

Targeting Angiogenesis and Tumor Cell Proliferation

Inhibition of VEGFR, EGFR, and RET kinase signaling

Vascular endothelial growth factor receptor

Vascular endothelial growth factor (VEGF) is a pro-angiogenic factor that acts on endothelial cells and plays a pivotal role in their proliferation, migration, and survival.1,2 Over-expression of VEGF and VEGF receptors (VEGFRs) correlates with increased tumor growth rate, microvessel density/proliferation, tumor metastatic potential, and poor patient prognosis in a variety of malignancies.1,3

Epidermal growth factor receptor

Epidermal growth factor receptor (EGFR) is a key driver in the processes of cell proliferation, and increased tumor EGFR levels have been associated with advanced disease, resistance to chemotherapy, and poor clinical prognosis.4

RET receptor

RET (rearranged during transfection) receptor is a novel oncogene that encodes the RET receptor tyrosine kinase. Mutations or translocation of the RET gene can lead to the development of specific tumor types such as familial medullary thyroid carcinoma and papillary thyroid carcinoma.5

Inhibition of VEGFR, EGFR, and RET kinase signaling – AstraZenecaOncology.com

View how targeting angiogenesis and tumor cell proliferation through inhibition of VEGFR, EGFR, and RET kinase signaling may impact cancer. Click the play button below.

 

Next: Targeting Angiogenesis: VEGF Signaling Inhibition
     
 

 

References
  1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
  2. Risau W. Mechanisms of angiogenesis. Nature. 1997;386: 671-674.
  3. Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de Water L, Senger DR. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol.
    1995;107:233-235.
  4. Herbst R. Targeting the epidermal growth factor receptor: prognostic and clinical implications. Eur J Cancer. 2003;1(suppl):9-15.
  5. Kodama Y, Asai N, Kawai K, et al. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci. 2005;96:143-148.